Cardiotoxicity is one of the major concerns for all new clinical compounds. To address this concern and the trend toward animal-free testing, ReproCELL became the world’s first commercial provider of human iPS cell-derived cardiomyocytes and services (since 2008). Called QTempo, this service (available in Japan) is an in vitro safety pharmacology assay service using beating cardiomyocytes derived from iPS cells. Furthermore, ReproCELL’s cardiomyocyte products and services can be flexibly tailored to the customers’ needs by genetic manipulation, use of patient-derived source material, or other collaborations. Today, ReproCELL is a recognized leader in cardiomyoctye applications and tools for research and development.
Media and Reagents
See all stem cell media.